Queen's Birthday Honour for Professor Georgina Long
8 June 2020
Congratulations to Melanoma Institute Australia Co-Medical Director, Professor Georgina Long, who has been recognised in the 2020 Queen’s Birthday Honours List announced today by the Governor-General.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
‘This is well deserved recognition of Professor Long’s lifesaving work and ground-breaking research,’ said fellow MIA Co-Medical Director, Professor Richard Scolyer. ‘She has changed the face of melanoma treatment around the world and many thousands of people are alive today thanks to her intellect, determination and passion.
‘It is due to her research and thought leadership globally that the world is now realistically looking towards a day with zero deaths from melanoma,’ he added.
Professor Long is one of the world’s most renowned melanoma clinicians and researchers with her clinical trials tripling life expectancy for some advanced melanoma patients and essentially curing others.
She leads the clinical trials team at MIA, with a focus on targeted therapy and immune-oncology in melanoma, and is Principal Investigator on Phase I, II and III trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases.
Professor Long is a fierce advocate that recent advances and breakthroughs in melanoma treatment stem from the collective effort of the dedicated multi-disciplinary team at MIA that she co-leads with her colleague and friend Professor Scolyer.
In a double world first, she is the first woman and the first Australian to be President of the prestigious US-based Society for Melanoma Research (SMR). She has authored over 300 publications in melanoma clinical and translational research, including in the world’s leading scientific high-impact journals such as the New England Journal of Medicine and The Lancet, and has presented at hundreds of international conferences.
Professor Long’s Queen’s Birthday Honour follows numerous awards including being named the 2018 Outstanding Researcher of the Year at the NSW Premiers Awards for Outstanding Cancer Research and receiving the prestigious Research Australia, GSK Research Excellence Award in 2018 and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research in 2016.
‘Professor Long’s recognition in the Queen’s Birthday Honours List is a proud day for all of us here at Melanoma Institute Australia,’ said CEO Matthew Browne.
‘Not only is she saving lives and changing the future for melanoma patients around the world, but she is also an inspiring role model for all young Australians, particularly women, who may be working towards a career in science and medicine,’ he said.
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
Research achievements by MIA were celebrated at the annual Sydney Medical School recently.
In this Global Research Report we showcase advances in medical oncology, reveal unexpected pathology in acral and skin melanoma, and uncover biomarkers and new gene targets for melanoma.
Professor’s Long and Scolyer are well known in the academic community and beloved by their patients. But we wanted to get to know our new Conjoint Medical Directors a little more and hear their plans on making an impact on melanoma.
Wyong Rugby League Club Group has joined forces with Melanoma Institute Australia to help end melanoma for future generations.
Melanoma research has reached a milestone with the 10,000th patient giving their permission for their blood and tissue samples to be used in the world’s largest melanoma biospecimen bank.
MIA's researchers and clinicians are in Seattle, USA, today sharing their research findings at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium.
Two of the world’s best minds in melanoma have taken over the academic and clinical leadership of Melanoma Institute Australia (MIA). Professor Georgina Long and Professor Richard Scolyer are the new Conjoint Medical Directors of MIA, and are shaping the future direction of melanoma research, treatment and education.
Meet Georgia, our Clinica Nurse Consultant who provides vital care and education for patients throughout their treatment.
Australia, we need to talk. This week’s dramatic episodes of Married At First Sight have highlighted a tragedy which is ripping Australian families apart. Yet no one is talking about it.
To celebrate International Women's Day 2017, MIA shares how some of the women who inspire the way we work every day, are showing their commitment to accelerate gender parity.
We welcome Mr Grant King to the position of Chairman of the Board of Melanoma Institute Australia, following the retirement of Mr Reg Richardson AM who led the organisation for 10 years.
Congratulations to PhD Student, Tuba Nur Gide who was awarded a NSW National Council of Women Australia Day Award for her PhD research work.
Melanoma Institute Australia, is joining forces with the Wollongong Wolves Football Club in the battle to reduce Australia’s melanoma rates.
A new research project will evaluate the benefits and economic implications of CT and PET/CT imaging in patients with asymptomatic Stage III melanoma.
Sunscreen tips for a skin smart summer with the help of Professor Pascale Guitera, Dermatologist Associate for Melanoma Institute Australia.
Although survival rates for people with skin melanoma are increasing, these promises of hope are not being seen in uveal melanoma. Researchers are desperately trying to uncover new ways to treat this disease.
Lucinda Ryan and Carole Renouf talking about melanoma preventation and awareness on 720 ABC Perth.
Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.